HealthCo Healthcare and Wellness REIT (ASX: HCW) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

HealthCo Healthcare and Wellness REIT Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $462.15 million
P/E Ratio 67.62
Dividend Yield 7.38%
Shares Outstanding 550.18 million
Earnings per share -0.007
Dividend per share 0.08
Year To Date Return -17.65%
Earnings Yield 1.48%
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

HealthCo Healthcare and Wellness REIT (ASX: HCW)
Latest News

Middle age caucasian man smiling confident drinking coffee at home.
Dividend Investing

These buy-rated ASX dividend shares offer 6% yields

Analysts are bullish on these income options. Here's what they are forecasting.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Dividend Investing

Analysts name 4 ASX dividend shares to buy for passive income

Let's see what sort of income these shares could provide investors.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Dividend Investing

3 high-yield ASX dividend shares that are great buys right now

Analysts have put buy ratings on these stocks. Let's see what they offer income investors.

Read more »

Person handing out $50 notes, symbolising ex-dividend date.
Dividend Investing

Buy these ASX dividend stocks with 7%+ yields

Analysts expect these stocks to make it rain dividends for their shareholders.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Dividend Investing

Should you buy BHP and these ASX dividend shares?

What are analysts saying about these income stocks?

Read more »

Happy man holding Australian dollar notes, representing dividends.
Dividend Investing

3 ASX dividend stocks with 7%+ yields to buy now

Analysts say these buy-rated shares will provide big dividend yields.

Read more »

Woman relaxing on her phone on her couch, symbolising passive income.
Dividend Investing

3 ASX dividend shares to buy with 6%+ yields

Analysts are feeling bullish about these dividend-payers.

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Dividend Investing

4 ASX dividend shares to buy next week

Brokers think income investors should be buying these stocks.

Read more »

Hand of a woman carrying a bag of money, representing the concept of saving money or earning dividends.
Dividend Investing

5 ASX dividend stocks to buy with 6%+ yields

Brokers have put buy ratings on these high-yield stocks.

Read more »

Happy young woman saving money in a piggy bank.
Dividend Investing

Buy these ASX dividend stocks for 5%+ yields

Analysts are forecasting some big dividend yields from these stocks.

Read more »

Young woman using computer laptop smiling in love showing heart symbol and shape with hands. as she switches from a big telco to Aussie Broadband which is capturing more market share
Dividend Investing

Why brokers love these ASX dividend stocks

They have good things to say about these income options.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Dividend Investing

Buy these ASX dividend stocks for 5% to 7% yields

Analysts say these are top options for income investors this week.

Read more »

Frequently Asked Questions

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
30 Dec 2024 $0.0210 0.00% Final 26 Feb 2025
27 Sep 2024 $0.0210 0.00% Interim 22 Nov 2024
27 Jun 2024 $0.0200 0.00% Final 22 Aug 2024
27 Mar 2024 $0.0200 0.00% Interim 22 May 2024
28 Dec 2023 $0.0200 0.00% Interim 21 Feb 2024
28 Sep 2023 $0.0200 0.00% Interim 29 Nov 2023
29 Jun 2023 $0.0200 0.00% Final 30 Aug 2023
01 May 2023 $0.0188 0.00% Interim 23 Jun 2023
29 Dec 2022 $0.0188 0.00% Interim 24 Feb 2023
29 Sep 2022 $0.0188 0.00% Interim 25 Nov 2022
29 Jun 2022 $0.0225 0.00% Final 22 Aug 2022
30 Mar 2022 $0.0225 0.00% Interim 20 May 2022
30 Dec 2021 $0.0300 0.00% Interim 25 Feb 2022

HCW ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About HealthCo Healthcare and Wellness REIT

HealthCo Healthcare and Wellness REIT (ASX: HCW) owns and manages a portfolio of commercial health and wellness real estate assets. The REIT is under the umbrella of HMC Capital (ASX: HMC), a listed asset manager that invests on behalf of individuals, large institutions, and super funds.

HealthCo Healthcare and Wellness REIT holds a $1.6 billion portfolio of 36 properties including hospitals, aged care, childcare, life sciences and research facilities as well as primary care and wellness assets. The portfolio covers Queensland, New South Wales, Victoria, and Western Australia with a weighted average lease expiry (WALE) of 12 years. 

HCW Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
23 May 2025 $0.84 $0.01 1.20% 1,208,715 $0.82 $0.85 $0.82
22 May 2025 $0.83 $-0.01 -1.20% 1,553,096 $0.82 $0.85 $0.82
21 May 2025 $0.84 $-0.01 -1.18% 1,273,285 $0.85 $0.85 $0.82
20 May 2025 $0.85 $0.01 1.20% 1,627,664 $0.84 $0.85 $0.82
19 May 2025 $0.84 $-0.01 -1.18% 1,325,403 $0.85 $0.86 $0.83
16 May 2025 $0.85 $0.02 2.41% 1,186,433 $0.83 $0.86 $0.83
15 May 2025 $0.83 $0.01 1.22% 1,023,747 $0.82 $0.84 $0.82
14 May 2025 $0.82 $-0.01 -1.20% 1,433,448 $0.83 $0.84 $0.82
13 May 2025 $0.83 $0.02 2.45% 2,084,178 $0.82 $0.84 $0.82
12 May 2025 $0.82 $-0.02 -2.41% 2,329,511 $0.84 $0.84 $0.82
09 May 2025 $0.83 $-0.04 -4.62% 3,834,011 $0.85 $0.86 $0.80
08 May 2025 $0.87 $0.01 1.17% 1,944,513 $0.84 $0.87 $0.84
07 May 2025 $0.86 $0.00 0.00% 847,095 $0.84 $0.86 $0.84
06 May 2025 $0.86 $0.01 1.18% 533,081 $0.86 $0.86 $0.85
05 May 2025 $0.85 $-0.02 -2.31% 859,102 $0.87 $0.88 $0.85
02 May 2025 $0.87 $0.01 1.17% 2,896,403 $0.85 $0.87 $0.85
01 May 2025 $0.86 $0.02 2.38% 1,566,040 $0.83 $0.86 $0.83
30 Apr 2025 $0.84 $0.01 1.20% 2,085,987 $0.84 $0.84 $0.83
29 Apr 2025 $0.83 $0.02 2.45% 2,117,907 $0.82 $0.84 $0.81
28 Apr 2025 $0.82 $-0.02 -2.41% 1,134,431 $0.83 $0.83 $0.81

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Feb 2025 Kelly O'Dwyer Buy 16,377 $16,049
As advised by the company. Tranche 1 of 2 of the acquisition of units
pursuant to participation in the FY25
voluntary non-executive director unit
acquisition arrangement as summarised in
HCW's Product Disclosure Statement dated 2
August 2021.
27 Feb 2025 Joseph Carrozzi Buy 16,079 $15,757
As advised by the company. Tranche 1 of 2 of the acquisition of units
pursuant to participation in the FY25
voluntary non-executive director unit
acquisition arrangement as summarised in
HCW's Product Disclosure Statement dated 2
August 2021.
27 Feb 2025 Natalie Meyenn Buy 19,361 $18,973
As advised by the company. Tranche 1 of 2 of the acquisition of units
pursuant to participation in the FY25
voluntary non-executive director unit
acquisition arrangement as summarised in
HCW's Product Disclosure Statement dated 2
August 2021.
19 Dec 2024 Stephanie Lai Buy 87,500 $88,733
On-market trade.
18 Dec 2024 Stephanie Lai Buy 12,500 $12,875
On-market trade.
02 Sep 2024 Natalie Meyenn Buy 15,310 $18,678
As advised by the company. Tranche 2 of 2 of the acquisition of units
pursuant to participation in the FY24
voluntary non-executive director unit
acquisition
02 Sep 2024 Kelly O'Dwyer Buy 12,824 $15,645
As advised by the company. Tranche 2 of 2 of the acquisition of units
pursuant to participation in the FY24
voluntary non-executive director unit
acquisition
02 Sep 2024 Joseph Carrozzi Buy 12,513 $15,265
As advised by the company. Tranche 2 of 2 of the acquisition of units
pursuant to participation in the FY24
voluntary non-executive director unit
acquisition

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Christopher Graham Roberts Non-Executive Director Aug 2021
Dr Roberts has over 40 years of experience in the medical device industry serving a number of senior management positions. He was the former CEO of Cochlear from 2004 to 2015 and is presently a member of the Cochlear Foundation Board and a Non-Executive Director of Sigma Healthcare Limited, Clarity Pharmaceuticals Limited, HMC Capital Partners Fund 1, Atmo Biosciences Ltd, Centenary Institute of Medical Research and Nutromics Pty Ltd. He was also the Executive Vice President of ResMed from 1992 to 2003, and a director until 2017. Chris was a former Chair of Research Australia from 2004 to 2010.
Ms Stephanie Mei-Nga Lai Non-Executive Director Aug 2021
Ms Lai e has over 25 years of experience, is a Chartered Accountant and is a former Transaction Services partner of Deloitte and KPMG. She has experience providing due diligence and advisory services, including forecast reviews to listed entities, sovereign wealth funds, wealth managers and private equity. She is Chair of Risk Committee.
Mr David Anthony Di Pilla Non-Executive Director Jul 2021
Mr Pilla has over 30 years of experience in investment banking, strategic advisory and consulting, and corporate leadership as a Director and CEO. During his 20 years of investment banking career, David was Managing Director of UBS Investment Bank for over 15 years and during this time led some of Australia's landmark transactions across corporate M&A, Equity & Debt Capital Markets. Prior to his time at UBS, David reached the position of Vice President, Investment Banking at JP Morgan.
Hon Kelly Megan O'Dwyer Non-Executive Director Aug 2021
Ms O'Dwyer previously served in the Australian Parliament as a Senior Cabinet Minister holding a number of key economic portfolios including Minister for Jobs and Industrial Relations, Minister for Revenue and Financial Services, Minister for Small Business, and Assistant Treasurer. She also served on the Cabinet's Budget Committee (the Expenditure Review Committee) and held the portfolios of Minister for Women, as well as Minister Assisting the Prime Minister with the Public Service. Prior to entering Parliament, Kelly worked in law, government and finance and brings insights across a range of sectors including funds management, superannuation, workplace relations, foreign investment, law and banking.
Mr Joseph Carrozzi Non-Executive ChairmanNon-Executive Director Aug 2021
Mr Carrozzi has over 25 years of experience as a managing partner in the Big 4 professional services firms. He has experience in infrastructure, health and medical research as well as sectors which are highly regulated. He is currently the Chair of the Centenary Institute for Medical Research, the Angus Knight Group, as well as a board member of the National Intermodal Corporation, the NSW Business Chamber, Football Australia, Aurrum Pty Ltd and ServiceGen Pty Ltd. Joseph was formerly Chair of the Sydney Harbour Federation Trust and Deputy Chair of the NSW Institute of Sport. He is also a member of Risk Committee.
Ms Natalie Jane Meyenn Non-Executive Director Aug 2021
Ms Meyenn has over 25 years of experience in financial services and investing globally. She was Head and Chair of the Investment Committee for MLC Private Equity and is currently co-founder of an agriculture investment firm and adviser and/or investment committee member to a small number of asset management, private equity and non-profits including New Energy Nexus and Yielco Investments. She worked in investment banking (M&A, capital markets and public finance) for Goldman Sachs and Bear Stearns in New York and Sydney and for the World Bank on micro-credit, project finance and climate impact mitigation in Asia, Africa and the Pacific Islands. She is also a member of Risk Committee.
Mr Andrew Selim Company SecretaryGeneral Counsel
-
Andrew Selim Company SecretaryGeneral Counsel
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Home Consortium Developments Limited 89,871,409 16.02%
J P Morgan Nominees Australia Pty Limited 80,211,627 14.30%
HSBC Custody Nominees (Australia) Limited 76,429,553 13.62%
Citicorp Nominees Pty Limited 36,237,475 6.46%
Home Consortium Limited 35,034,393 6.24%
BNP Paribas Noms Pty Ltd 29,916,793 5.33%
Netwealth Investments Limited (Wrap Services A/C) 7,033,080 1.25%
National Nominees Limited 5,140,105 0.92%
BNP Paribas Nominees Pty Ltd (HUB24 Custodial Serv Ltd) 4,858,930 0.87%
BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 4,444,729 0.79%
HSBC Custody Nominees (Australia) Limited A/C 2 3,273,968 0.58%
HSBC Custody Nominees (Australia) Limited (NT COMNWLTH Super Corp A/C) 2,540,200 0.45%
Netwealth Investments Limited (Super Services A/C) 2,284,185 0.41%
BNP Paribas Nominees Pty Ltd (Pitcher Partners) 2,282,189 0.41%
Goat Properties Pty Ltd 1,986,390 0.35%
Citicorp Nominees Pty Limited (Colonial First State Inv A/C) 1,609,218 0.29%
Sword Excalibur Equities Pty Ltd (Sword Excalibur EQ 2 A/C) 1,597,222 0.28%
Glengallan Investments Pty Ltd 1,188,249 0.21%
Premium Capital (Aust) Pty Ltd 1,082,000 0.19%
Seymour Group Pty Ltd 1,078,000 0.19%

Profile

since

Note